



<b>Substitute for form 1449A/PTO</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/717,597
				Filing Date	November 21, 2003
				First Named Inventor	Natalie C. TWINE <i>et al.</i>
				Art Unit	1631
				Examiner Name	Mary K. Zeman
Sheet	1	of	1	Attorney Docket Number	031896-012000 (AM101055)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
S		U.S. - 2004/0235020 A1	11-25-2004	BURCZYNSKI. M. <i>et al.</i>	
		U.S. - 2004/0175743 A1	09-09-2004	BURCZYNSKI. M. <i>et al.</i>	
		U.S. - 60/427,982		BURCZYNSKI. M. <i>et al.</i>	
		U.S. - 60/459,782		TWINE, N. C. <i>et al.</i>	
		U.S. - 60/446,133		BURCZYNSKI. M. <i>et al.</i>	
		U.S. - 60/538,246		BURCZYNSKI. M. <i>et al.</i>	
		U.S. - 60/466,067		DORNER, A. <i>et al.</i>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
S		WO 2004/097052 A2	11-11-2004	BURCZYNSKI. M. <i>et al.</i>		
		WO 2004/094673 A2	11-04-2004	BURCZYNSKI. M. <i>et al.</i>		
		WO 2004/072265 A2	08-26-2004	BURCZYNSKI. M. <i>et al.</i>		


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
S			

Examiner Signature		Date Considered	11/30/03
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	2	<b>Complete if Known</b>	
				Application Number	10/717,597
				Filing Date	November 21, 2003
				First Named Inventor	TWINE et al
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
				Attorney Docket Number	031896-012000 (AM 101080)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
S		WO00/040749		07-13-00	Chin		
		WO02/040000		05-23-02	Dukart et al.		
		WO01/081916		11-01-01	Ma et al.		
		WO03/032813		04-24-03	Gerritsen et al.		
		WO04/072265		08-26-04	Donner et al.		
		WO04/048933		06-10-04	Stover et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
S		BURCZYNSKI et al., "Pharmacogenomic expression profiling of renal cell carcinoma in a phase II trial of CCI-779: identification of surrogate markers of disease and predictors of outcome in the compartment of peripheral blood", <i>European Journal of Cancer, Pergamon Press, Oxford, GB</i> , vol. 38, November 11, 2002, page S51	
		SCHULZE-KOOPS, H. et al., "Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1)", <i>Clinical and Experimental Immunology</i> , vol. 106, no. 2, November 1996, pages 190-196	
		DIPAOLA, R.S., et al., "Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies," <i>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</i> , Vol. 17, no. 7, July 1999, pages 2213-2218	
		"Product Catalogue", January 2001, <i>Affymetrix</i> , pages 1	
S		LICHTENFELS, R. et al., "Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses", <i>Biochimica et Biophysica Acta</i> , Vol. 1646, No. 1-2, March 21, 2003, pages 21-31	
		SU, ANDREW I., et al., "Large-scale analysis of the human and mouse transcriptomes," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , Vol. 99, No. 7, April 2, 2002, pages 4465-4470	
		DATABASE SOURCE Online!, <a href="http://genome-www5.stanford.edu/cgi-bin/source/expressSearch?option=cluster&amp;criteria=Hs.171501&amp;organism=Hs">http://genome-www5.stanford.edu/cgi-bin/source/expressSearch?option=cluster&amp;criteria=Hs.171501&amp;organism=Hs</a> abstract	

Examiner Signature		Date Considered	11/30/05
--------------------	--	-----------------	----------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



<b>Substitute for form 1449B*PTO</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/717,597
				Filing Date	November 21, 2003
				First Named Inventor	TWINE et al
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	2	Of	2	Attorney Docket Number	031896-012000 (AM 101080)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ELIT, LAURIE, "CCI-779 Wyeth," <i>Current Opinion in Investigational Drugs (London, England: 2000)</i> , Vol. 3, No. 8, August 2002, pages 1249-1253	
		PERALBA, JOSEP MARIA, et al., "Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients," <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , Vol. 9, No. 8, August 1, 2003, pages 2887-2892	
		RJNINGER, J., et al., "Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity", <i>Drug Discovery Today United Kingdom</i> , Vol. 5, No. 12, December 1, 2000, pages 560-568	
		PCT International Search Report; PCT/US2004/006601; November 19, 2004; 4 pages	

Examiner Signature		Date Considered	11/30/05
-----------------------	---	--------------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/717,597
				Filing Date	November 21, 2003
				First Named Inventor	Natalie C. TWINE
				Art Unit	1631
				Examiner Name	Channing Mahatan
Sheet	1	of	1	Attorney Docket Number	031896-012000

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
52		US-5,840,506	11-24-1998	Giordano	
		US-6,110,675	08-29-2000	Cohen et al.	
		US-6,190,857	02-20-2001	Ralph et al.	
		US-6,317,731	11-13-2001	Luciano	
		US-2001/0053548 A1	12-20-2001	Rybak et al.	
		US-2002/0042072 A1	04-11-2002	Van Meel	
		US-2002/0132274 A1	09-19-2002	Nevalainen et al.	
		US-2002/0164664 A1	11-07-2002	Hlavaty et al.	
		US-2002/0168638 A1	11-14-2002	Schlegel et al.	
		US-2002/0182614 A1	12-05-2002	Gillis et al.	
		US-6,647,341	11-11-2003	Golub et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
52		DEPRIMO ET AL., "EXPRESSION PROFILING OF BLOOD SAMPLES FROM AN SU5416 PHASE III METASTATIC COLORECTAL CANCER CLINICAL TRIAL: A NOVEL STRATEGY FOR BIOMARKER IDENTIFICATION", BIOMED CENTRAL, PP. 1471-2407	

Examiner Signature		Date Considered	11/30/03
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet

1

of

7

**Complete if Known**

Application Number

10/717,597

Filing Date

November 21, 2003

**First Named Inventor**

TWINE et al

### Art Unit

Not yet assigned

**Examiner Name**

Not yet assigned

Attorney Docket Number

031896-01200

## U.S. PATENT DOCUMENTS

[illegible]

~~Date~~  
~~Considered~~

11/30/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.






Substitute for Form PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/717,597
		Filing Date	November 21, 2003
		First Named Inventor	TWINE et al
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet	3	of	7
		Attorney Docket Number	031896012000

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	✓	ALTSCHUL ET AL.; "GAPPED BLAST AND PSI-BLAST: A NEW GENERATION OF PROTEIN DATABASE SEARCH PROGRAMS", NUCLEIC ACIDS RESEARCH, 1997, PP. 3389-3402, VOL. 25, NO. 17, OXFORD UNIVERSITY PRESS	
	✓	BERGER P. ET AL.; "LOSS OF PHOSPHATASE ACTIVITY IN MYOTUBULARIN-RELATED PROTEIN 2 IS ASSOCIATED WITH CHARCOT-MARIE TOOTH DISEASE TYPE 4B1", HUMAN MOLECULAR GENETICS, 2002, PP. 1569-1579, VOL. 11, NO. 13, OXFORD UNIVERSITY PRESS	
	✓	BOE R. ET AL.; "THE PROTEIN PHOSPHATASE INHIBITOR OKADAIC ACID INDUCES MORPHOLOGICAL CHANGES TYPICAL OF APOPTOSIS IN MAMMALIAN CELLS", EXPERIMENTAL CELL RESEARCH 195, 1991, PP. 237-246, ACADEMIC PRESS, INC.	
	✓	BOTTINI N. ET AL.; "LOW-MOLECULAR-WEIGHT PROTEIN TYROSINE PHOSPHATASE AND HUMAN DISEASE: IN SEARCH OF BIOCHEMICAL MECHANISMS", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2002 pp. 95-104, vol. 50,	
	✓	BROWN-SHIMER, ET AL.; "EFFECT OF PROTEIN TYROSINE PHOSPHATASE 1b EXPRESSION ON TRANSFORMATION BY THE HUMAN neu ONCOGENE", CANCER RESEARCH, 52, 1992, PP. 478-48	
	✓	CHEN ET AL.; "THE MYOTONIC DYSTROPHY KINASE-RELATED Cdc42-BINDING KINASE IS INVOLVED IN THE REGULATION OF NEURITE OUTGROWTH IN PC12 CELLS", THE JOURNAL OF BIOLOGICAL CHEMISTRY 1999, PP. 19901-19905, VOL. 274, NO. 28, THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC.	
	✓	DELAGRAVE ET AL.; "RECURSIVE ENSEMBLE MUTAGENESIS", PROTEIN ENGINEERING, 1993, PP. 327-331, VOL. 6 NO. 3, OXFORD UNIVERSITY PRESS	
	✓	DONG ET AL.; "Cdc42 ANTAGONIZES INDUCTIVE ACTION OF cAMP ON CELL SHAPE, VIA EFFECTS OF THE MYOTONIC DYSTROPHY KINASE-RELATED Cdc42-BINDING KINASE (MRCK) ON MYOSIN LIGHT CHAIN PHOSPHORYLATION", EUROPEAN JOURNAL OF CELL BIOLOGY APRIL 2002, PP. 231-242, VOL. 81	

Examiner Signature		Date Considered	1/130/05
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for Form PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/717,597
		Filing Date	November 21, 2003
		First Named Inventor	TWINE et al.
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
		Attorney Docket Number	031896-012000
Sheet	4	of	7

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	✓	ENGELMAN ET AL.; "IDENTIFYING NONPOLAR TRANSBILAYER HELICES IN AMINO ACID SEQUENCES OF MEMBRANE PROTEINS", ANN. REV. BIOPHYS. CHEM. 1986, PP. 321-353, VOL. 15, ANNUAL REVIEWS INC.	
	✓	FLOREA ET AL.; "A COMPUTER PROGRAM FOR ALIGNING A cDNA SEQUENCE WITH A GENOMIC DNA SEQUENCE", GENOME RESEARCH 1998, PP. 967-974, VOL. 8, COLD SPRING HARBOR LABORATORY PRESS	
	✓	GOSSEN ET AL.; "TRANSCRIPTIONAL ACTIVATION BY TETRACYCLINES IN MAMMALIAN CELLS", SCIENCE JUNE 23, 1995, PP. 1766-1769, VOL. 268	
	✓	GUATELLI ET AL.; "ISOTHERMAL, IN VITRO AMPLIFICATION OF NUCLEIC ACIDS BY A MULTIENZYME REACTION MODELED AFTER RETROVIRAL REPLICATION", PROC. NATL. ACAD. SCI. USA, MARCH 1990, PP.1874-1878, VOL. 87	
	✓	HASELOFF ET AL.; "SIMPLE RNA ENZYMES WITH NEW AND HIGHLY SPECIFIC ENDORIBONUCLEASE ACTIVITIES", NATURE, AUGUST 18, 1988, PP. 585-591, VOL. 334	
	✓	HYRUP ET AL.; "PEPTIDE NUCLEIC ACIDS (PNA): SYNTHESIS, PROPERTIES AND POTENTIAL APPLICATIONS", BIOORGANIC & MEDICINAL CHEMISTRY, 1996, PP. 5-23, VOL. 4, NO. 1, ELSEVIER SCIENCE LTD., GREAT BRITAIN	
54	✓	ISHIDA ET AL.; "TREATMENT OF MYELOID LEUKEMIC CELLS WITH THE PHOSPHATASE INHIBITOR OKADAIC ACID INDUCES CELL CYCLE ARREST AT EITHER G1/S OR G2/M DEPENDING ON DOSE", JOURNAL OF CELLULAR PHYSIOLOGY, 1992, PP. 484-492	
	✓	JANSSENS ET AL.; "PROTEIN PHOSPHATASE 2A: A HIGHLY REGULATED FAMILY OF SERINE/THREONINE PHOSPHATASES IMPLICATED IN CELL GROWTH AND SIGNALING," BIOCHEM. J., 353, 2001, PP 417-43	
	✓	KEDRA ET AL.; "THE GERMINAL CENTER KINASE GENE AND A NOVEL CDC25-LIKE GENE ARE LOCATED IN THE VICINITY OF THE PYGM GENE ON 11q13", HUM. GENET., 1997, PP. 611-619, VOL. 100	

Examiner Signature		Date Considered	11/30/03
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.






Substitute for Form PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/717,597
		Filing Date	November 21, 2003
		First Named Inventor	TWINE et al.
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet	5	of	7
		Attorney Docket Number	031896-012000

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	✓	KEEN ET AL.; <b>RAPID DETECTION OF SINGLE BASE MISMATCHES AS HETERODUPLEXES ON HYDROLINK GELS</b> , TRENDS IN GENETICS, 1997, P. 5, VOL. 7	
	✓	KWOH ET AL.; <b>"TRANSCRIPTION-BASED AMPLIFICATION SYSTEM AND DETECTION OF AMPLIFIED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 WITH A BEAD-BASED SANDWICH HYBRIDIZATION FORMAT"</b> , PROC. NATL. ACAD. SCI. USA, FEBRUARY 1989, PP. 1173-1177, VOL. 86	
	✓	LAM ET AL.; <b>"CHARACTERIZATION OF A MONOCLONAL ANTIBODY PANEL SHOWS THAT THE MYOTONIC DYSTROPHY PROTEIN KINASE, DMPK, IS EXPRESSED ALMOST EXCLUSIVELY IN MUSCLE AND HEART"</b> , HUMAN MOLECULAR GENETICS, 2000, PP. 2167-2173, VOL. 9, NO. 4, OXFORD UNIVERSITY PRESS	
	✓	LEE ET AL.; <b>"EXPRESSION OF SMALL INTERFERING RNAs TARGETED AGAINST HIV-1 rev TRANSCRIPTS IN HUMAN CELLS"</b> , NATURE BIOTECHNOLOGY, MAY 2002, PP. 500505, VOL. 19	
✓	✓	LEUNG ET AL.; <b>"MYOTONIC DYSTROPHY KINASE-RELATED Cdc42-BINDING KINASE ACTS AS A Cdc42 EFFECTOR IN PROMOTING CYTOSKELETAL REORGANIZATION"</b> , MOLECULAR AND CELLULAR BIOLOGY, JANUARY 1998, PP. 130-140, VOL. 18, NO. 1, AMERICAN SOCIETY FOR MICROBIOLOGY	
	✓	LIZARDI ET AL.; <b>"EXPONENTIAL AMPLIFICATION OF RECOMBINANT-RNA HYBRIDIZATION PROBES"</b> , BIOTECHNOLOGY, OCTOBER 1988, PP. 1197-1202, VOL. 6	
	✓	MARATEA ET AL.; <b>"DELETION AND FUSION ANALYSIS OF THE PHAGE Øx174 LYSIS GENE E"</b> , GENE, 1985, PP. 39-46, VOL. 40, ELSEVIER SCIENCE PUBLISHERS	

Examiner Signature		Date Considered	11/30/05
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number		10/717,597	
				Filing Date		November 21, 2003	
				First Named Inventor		TWINE et al.	
				Group Art Unit		Not yet assigned	
				Examiner Name		Not yet assigned	
Sheet	6	of	7	Attorney Docket Number		031896-012000	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
✓ ✓ ✓ ✓ ✓ ✓ ✓	✓	MEYERS ET AL.; "OPTIMAL ALIGNMENTS IN LINEAR SPACE", CABIOS, 1988, PP. 11-17, VOL. 4, NO. 1, PRESS LIMITED, OXFORD ENGLAND	
	✓	MURPHY ET AL.; "GENETIC CONSTRUCTION, EXPRESSION, AND MELANOMA-SELECTIVE CYTOTOXICITY OF A DIPHTHERIA TOXIN-RELATED $\alpha$ -MELANOMA-STIMULATING HORMONE FUSION PROTEIN", PROC. NATL. ACA. SCI. USA, NOVEMBER 1986, PP. 8258-8262, VO. 83	
	✓	NEEDLEMAN ET AL.; "A GENERAL METHOD APPLICABLE TO THE SEARCH FOR SIMILARITIES IN THE AMINO ACID SEQUENCE OF TOW PROTEINS", J. MOL. BIO., 1970, PP. 443-453, VOL. 48	
	✓	NO ET AL.; "ECDYSONE-INDUCIBLE GENE EXPRESSION IN MAMMALIAN CELLS AND TRANSGENIC MICE", PROC. NATL. ACAD. SCI. USA, APRIL 1996, PP. 3346-3351, VOL. 93	
	✓	NOMURA ET AL.; "ENHANCEMENT BY CYCLOSPORIN A OF TAXOL-INDUCED APOPTOSIS OF HUMAN URINARY BLADDER CANCER CELLS", UROL RES, 2002, PP. 102-111, VOL. 30	
	✓	O'GORMAN ET AL.; "RECOMBINASE-MEDIATED GENE ACTIVATION AND SITE-SPECIFIC INTEGRATION IN MAMMALIAN CELLS", SCIENCE, MARCH 1991, PP. 1351-1355	
	✓	✓	ROSENBAUM ET AL.; "TEMPERATURE-GRADIENT GEL ELECTROPHORESIS", BIOPHYSICAL CHEMISTRY, 1987, PP. 235-246, VOL. 26
✓	✓	SAIKI ET AL.; "GENETIC ANALYSIS OF AMPLIFIED DNA WITH IMMOBILIZED SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBES", PROC. NATL. ACAD. SCI. USA, AUGUST 1989, PP. 6230-6234, VOL. 86	

Examiner Signature		Date Considered	11/30/03
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	10/717,597		
		Filing Date	November 21, 2003		
		First Named Inventor	TWINE et al		
		Group Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
Sheet	7	of	7	Attorney Docket Number	031896-012000

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	✓	STRAUB ET AL.; "GENOME-WIDE SCANS OF THREE INDEPENDENT SETS OF 90 IRISH MULTIPLEX SCHIZOPHRENIA FAMILIES AND FOLLOW-UP OF SELECTED REGIONS IN ALL FAMILIES PROVIDES EVIDENCE FOR MULTIPLE SUSCEPTIBILITY GENES", MOL. PSYCHIATRY, 2002, PP. 542-559, VOL. 7, NO. 6	
	✓	SUI ET AL.; "A DNA VECTOR-BASED RNAi TECHNOLOGY TO SUPPRESS GENE EXPRESSION IN MAMMALIAN CELLS", PROC. NATL. ACAD. SCI., APRIL 16, 2002, PP. 5515-5520, VOL. 99, NO. 8	
	✓	TAN ET AL.; "PHOSPHORYLATION OF A NOVEL MYOSIN BINDING SUBUNIT OF PROTEIN PHOSPHATASE 1 REVEALS A CONSERVED MECHANISM IN THE REGULATION OF ACTIN CYTOSKELETON", THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, PP. 21209-21216, VOL. 276, NO. 24	
	✓	TAN ET AL.; "INTERMOLECULAR AND INTRAMOLECULAR INTERACTIONS REGULATE CATALYTIC ACTIVITY OF MYOTONIC DYSTROPHY KINASE-RELATED Cdc42-BINDING KINASE α", MOLECULAR AND CELLULAR BIOLOGY, APRIL 2001, PP. 2767-2778, VOL. 21, NO. 8	
	✓	WANG ET AL.; "LIGAND-INDUCIBLE AND LIVER-SPECIFIC TARGET GENE EXPRESSION IN TRANSGENIC MICE", NATURE BIOTECHNOLOGY, MARCH 1997, PP. 239-243, VOL. 15	
W	✓	WARY ET AL.; "A HOMOZYGOUS DELETION WITHIN THE CARBONIC ANHYDRASE-LIKE DOMAIN OF THE Ptpg GENE IN MURINE L-CELLS", CANCER RESEARCH, APRIL 1, 1993, PP. 478-482, VOL. 53	
W	✓	WILMUT ET AL.; "VIABLE OFFSPRING DERIVED FROM FETAL AND ADULT MAMMALIAN CELLS", LETTERS TO NATURE, FEBRUARY 1997, PP. 810-813, VOL. 385	
	✓	YE ET AL.; "REGULATED DELIVERY OF THERAPEUTIC PROTEINS AFTER IN VIVO SOMATIC CELL GENE TRANSFER," SCIENCE, JANUARY 1999, PP. 88-91, VOL. 283	
	✓	ZHAO ET AL.; "REVERSIBLE MODIFICATION OF TISSUE-TYPE PLASMINOGEN ACTIVATOR BY METHYLPHOSPHONATE ESTERS," BIOORGANIC & MEDICINAL CHEMISTRY, 1996, PP. 523-529, VOL. 4	
	✓	ZY; "PROTEIN TYROSINE PHOSPHATASES: STRUCTURE AND FUNCTION, SUBSTRATE SPECIFICITY, AND INHIBITOR DEVELOPMENT," ANNU REV PHARMACOL TOXICOL, 2002, PP. 209-34, VOL. 42	

Examiner Signature		Date Considered	11/30/05
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		<b>Complete if Known</b>			
		Application Number	10/717,597		
		Filing Date	November 21, 2003		
		First Named Inventor	Natalie C. TWINE <i>et al.</i>		
		Art Unit	1631		
		Examiner Name	Mary K. Zeman		
Sheet	1	of	2	Attorney Docket Number	031896-012000 (AM101055)

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
LW	/	U.S. - 6,288,220	09-11-2001	KAMBARA, H. <i>et al.</i>	/
		U.S. - 6,391,562	05-21-2002	KAMBARA, H. <i>et al.</i>	
		U.S. - 6,303,301	10-16-2001	MACK, D. H. <i>et al.</i>	
		U.S. - 6,087,098	06-11-2000	MCKIERNAN, J. M. <i>et al.</i>	

Examiner Signature	Date Considered
-----------------------	--------------------

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code <sup>3</sup> Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)				
LW	1	WO 2002/40717 A2		05-23-2002	MOHANLAL, R.W. <i>et al.</i>		

Examiner Signature	Date Considered
-----------------------	--------------------

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LW	/	International Search Report for PCT/US2004/004118, mailed 01/19/2005, 9 sheets	/
		International Search Report for PCT/US2004/013587, mailed 01/25/2005, 9 sheets	
		International Search Report for PCT/US2003/037481, mailed 08/23/2005, 3 sheets	
		A. H. KIBBE, Handbook of Pharmaceutical Excipients, 3 <sup>rd</sup> Edition, Pharmaceutical Press, London, U.K., 2000	
		Affymetrix GeneChip® Expression Analysis, Data Analysis Fundamentals	
		Affymetrix GeneChip® Expression Analysis Technical Manual	
		ARMSTRONG, S. A. <i>et al.</i> , MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia, <i>Nat. Genet.</i> , 30(1):41-47, 2002	
		BOSMA, A. J. <i>et al.</i> , Detection of circulating breast tumor cells by differential expression of marker genes, <i>Clin. Cancer Res.</i> , 8(6):1871-1877, 2002	
		COX, D. R., Regression models and life-tables, <i>Meeting of the Research Section of the Royal Statistical Society</i> , pp. 187-220, 1972	
		DAVIS, I. J. <i>et al.</i> , Cloning of an <i>Alpha-TFEB</i> fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation, <i>Proc. Natl. Acad. Sci. USA</i> , 100(10):6051-6056, 2003	
		DEPRIMO, S.E. <i>et al.</i> , Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification, <i>BMC Cancer</i> , 3(3):1-12, 2003	
		EISEN, M. B. <i>et al.</i> , Cluster analysis and display of genome-wide expression patterns, <i>Proc. Natl. Acad. Sci. USA</i> , 95:14863-14868, 1998	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

W673775.1



Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/717,597
				Filing Date	November 21, 2003
				First Named Inventor	Natalie C. TWINE <i>et al.</i>
				Art Unit	1631
				Examiner Name	Mary K. Zeman
Sheet	2	of	2	Attorney Docket Number	031896-012000 (AM 101080)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GOLUB, T. R. <i>et al.</i> , Molecular classification of cancer: class discovery and class prediction by gene expression monitoring, <i>Science</i> , 286(15):531-537, 1999	
		HILL, A. A. <i>et al.</i> , Genomic analysis of gene expression in <i>C. elegans</i> , <i>Science</i> , 290:809-812, 2000	
		HILL, A. A. <i>et al.</i> , Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls, <i>Genome Biology</i> , 2 (12):1-13, 2001	
		KOVACS, G. <i>et al.</i> , The Heidelberg classification of renal cell tumours, <i>J. Pathol.</i> , 183(2):131-133, 1997	
		LOCKHART, D. J. <i>et al.</i> , Expression monitoring by hybridization to high-density oligonucleotide arrays, <i>Nat. Biotechnol.</i> , 14(13):1675-1680, 1996	
		MOTZER, R. J. <i>et al.</i> , Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma, <i>J. Clin. Oncol.</i> , 17(8):2530-2540, 1999	
		PAI, S. M. <i>et al.</i> , Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex, <i>J. Clin. Pharmacol.</i> , 32(3):242-247, 1992	
		PARK, W.Y. <i>et al.</i> , Identification of radiation-specific responses from gene expression profile, <i>Oncogene</i> , 21(55):8521-8528, 2002	
		PERALBA, J.-M. <i>et al.</i> , Pharmacodynamic evaluation of the rapamycin ester CCI-779, <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , Volume 43, March 2002 (2002-2003), pp. 1000-1001, Abstract No. 4961, and 93 <sup>rd</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 06-10, 2002	
		POMEROY, S. L. <i>et al.</i> , Supplemental Information for Nature's Paper: Prediction of central nervous system embryonal tumour outcome based on gene expression, pp. 1-104, 2002	
		POMEROY, S. L. <i>et al.</i> , Prediction of central nervous system embryonal tumour outcome based on gene expression, <i>Nature</i> , 415(6870):436-442, 2002	
		RAMASWAMY, S. <i>et al.</i> , Multiclass cancer diagnosis using tumor gene expression signatures, <i>Proc. Natl. Acad. Sci. USA</i> , 98(26):15149-15154, 2001	
		SLONIM, D. K. <i>et al.</i> , Class prediction and discovery using gene expression data, <i>Proceedings of the Fourth Annual International Conference on "Computational Molecular Biology,"</i> TOKYO, JAPAN, pp. 263-272, 2000	
		SNEDECOR, G. W. and COCHRAN, W. G., Correlation, In <i>Statistical Methods</i> , Eight Edition, Chapter 10, pp. 177-195, Iowa State University Press, Ames, Iowa, 1989	
		SU, A. I. <i>et al.</i> , Molecular classification of human carcinomas by use of gene expression signatures, <i>Cancer Res.</i> , 61:7388-7393, 2001	
		VAN DE VIJVER, M. J. <i>et al.</i> , A gene-expression signature as a predictor of survival in breast cancer, <i>N. Engl. J. Med.</i> , 347(25):1999-2009, 2002	
		WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48, pp. 1-45, World Health Organization, Geneva, Switzerland, 1979	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.